CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Actinogen Medical Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Actinogen Medical Ltd
Select House
SE 901 L 9, 109 Pitt Street
Phone: +61 289647401p:+61 289647401 SYDNEY, NSW  2000  Australia Ticker: ACWACW
Business Summary
Actinogen Medical Limited is an Australia-based biotechnology company. The Company is engaged in the development of a therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. The Company is engaged in the development of its lead compound, Xanamem, as a therapy for Alzheimer’s Disease, Major Depressive Disorder, Fragile X Syndrome, and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. Xanamem’s mechanism is to control elevated levels of cortisol (stress hormone) in the brain through the inhibition of the cortisol synthesis enzyme, 11B-HSD1, without affecting production of cortisol by the adrenal glands, which is essential for the body’s normal functioning. Xanamem is a once-a-day pill designed to deliver high levels of cortisol control in key areas of the brain related to Alzheimer’s and other diseases such as the hippocampus and frontal cortex.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20256/30/2025Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board Geoffrey E.Brooke 3/24/2021 3/1/2017
Chief Executive Officer, Managing Director, Executive Director StevenGourlay 3/24/2021 3/12/2021
Chief Financial Officer WilliamSouter 2/5/2024 2/5/2024
9 additional Officers and Directors records available in full report.

Business Names
Business Name
ACW
Corticrine Ltd.

General Information
Outstanding Shares: 3,177,147,241 (As of 6/30/2025)
Shareholders: 5,425
Stock Exchange: ASX
Fax Number: +61 289647588


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, November 4, 2025